Long Term Integrated Safety Analysis Of Umbralisib (TGR-1202), A PI3K?/Ck1? Inhibitor With A Differentiated Safety Profile, In Patients With Relapsed/Refractory Lymphoid Malignancies

Drug Category : Array
Conference Category : Array
Lead Author : Davids M, et. al.
Published Date : 15/06/2018
Download Link : https://www.tgtherapeutics.com/wp-content/uploads/2019/03/Final-2018-Integrated-EHA1.pdf
Download Text : Download
Popup Confirmation? :
site-sidebar-layout : default
ast-site-content-layout : default
site-content-style : default
site-sidebar-style : default
theme-transparent-header-meta : default
stick-header-meta : default
astra-migrate-meta-layouts : set
Scroll to Top